SB-300, Jaguar's Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing Guidelines

Results of Initial Study Show that Jaguar's Equine Product Candidate for Treatment of Gastric Ulcers May Offer Horse Owners an Additional Advantage in the Competition Horse World, where Requirements Exist for Animals to Compete Free from the Effect of Any Drugs

Subscribe to the Harmany Newsletter

* indicates required
Email Format

View previous campaigns.

Please select all the ways you would like to hear from Harmany Equine:

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.